L. Simon, B. Ghaleh, L. Puybasset, J. Giudicelli, and A. Berdeaux, in the peri-infarction territory vs 1021±36 and 944±41 vessels/mm 2 in the remote non ischaemic territory in Control and Ivabradine, respectively. REFERENCES 1 Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs, J Pharmacol Exp Ther, vol.275, issue.2, pp.659-66, 1995.

X. Monnet, C. P. Ghaleh, B. Hittinger, L. Giudicelli, J. Berdeaux et al., Heart rate reduction during exercise-induced myocardial ischaemia and stunning, European Heart Journal, vol.25, issue.7, pp.579-86, 2004.
DOI : 10.1016/j.ehj.2003.10.010

G. Heusch, A. Skyschally, P. Gres, P. Van-caster, D. Schilawa et al., Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction, European Heart Journal, vol.29, issue.18, pp.2265-75, 2008.
DOI : 10.1093/eurheartj/ehn337

C. Thollon, C. Cambarrat, J. Vian, J. Prost, J. Peglion et al., Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49, British Journal of Pharmacology, vol.8, issue.Suppl. L, pp.37-42, 1994.
DOI : 10.1111/j.1476-5381.1994.tb13025.x

G. Lerebours, F. Mahlberg-gaudin, and C. Thuillez, Long-term heart rate reduction induced by the 14

A. Gomez, B. Schwaller, H. Porzig, G. Vassort, E. Niggli et al., Increased Exchange Current but Normal Ca2+ Transport via Na+-Ca2+ Exchange During Cardiac Hypertrophy After Myocardial Infarction, Circulation Research, vol.91, issue.4, pp.323-353, 2002.
DOI : 10.1161/01.RES.0000031384.55006.DB

R. Tissier, R. Souktani, P. Bruneval, J. Giudicelli, A. Berdeaux et al., Adenosine

B. Enriquez, A. Berdeaux, and B. Ghaleh, Pharmacological postconditioning with the phytoestrogen genistein, J Mol Cell Cardiol, vol.42, pp.79-87, 2007.
URL : https://hal.archives-ouvertes.fr/hal-00123556

L. Lucats, B. Ghaleh, C. P. Monnet, X. Bize, A. Berdeaux et al., or by ??-blockade has different effects on postsystolic wall thickening, British Journal of Pharmacology, vol.286, issue.3, pp.335-376, 2007.
DOI : 10.1038/sj.bjp.0706996

K. Kontula, H. Swan, and A. Marks, Sudden death in familial polymorphic ventricular tachycardia associated with calcium release channel (ryanodine receptor) leak, Circulation, vol.109, pp.3208-3222, 2004.

J. Mercadier, L. Hittinger, A. Berdeaux, and B. Ghaleh, The inotropic adaptation during late preconditioning against myocardial stunning is associated with an increase in FKBP12

F. Huang, J. Shan, S. Reiken, X. Wehrens, and A. Marks, Analysis of calstabin2 (FKBP12.6)-ryanodine receptor interactions: Rescue of heart failure by calstabin2 in mice, Proceedings of the National Academy of Sciences, vol.103, issue.9
DOI : 10.1073/pnas.0511282103

K. Ito, S. Shigematsu, T. Sato, T. Abe, Y. Li et al., JTV-519, a novel cardioprotective agent, improves the contractile recovery after ischaemia-reperfusion in coronary perfused guinea-pig ventricular muscles, British Journal of Pharmacology, vol.266, issue.4, pp.767-76, 2000.
DOI : 10.1038/sj.bjp.0703373

G. Heusch, Pleiotropic action(s) of the bradycardic agent ivabradine: cardiovascular protection beyond heart rate reduction, British Journal of Pharmacology, vol.33, issue.7, pp.970-971, 2008.
DOI : 10.1038/bjp.2008.347

E. Cerbai, L. Sartiani, P. Depaoli, R. Pino, M. Maccherini et al., The Properties of the Pacemaker Current IFin Human Ventricular Myocytes are Modulated by Cardiac Disease, Journal of Molecular and Cellular Cardiology, vol.33, issue.3, pp.441-449, 2001.
DOI : 10.1006/jmcc.2000.1316

J. Hoppe and U. , Direct evidence for calcium conductance of hyperpolarization-activated cyclic nucleotide-gated channels and human native If at physiological calcium concentrations

B. Guth, G. Heusch, R. Seitelberger, J. Ross, and J. , Elimination of exercise-induced regional myocardial dysfunction by a bradycardiac agent in dogs with chronic coronary stenosis, Circulation, vol.75, issue.3, pp.661-670, 1987.
DOI : 10.1161/01.CIR.75.3.661